Eric D Bateman1, Udo-Michael Goehring2, Frank Richard3, Henrik Watz4. 1. Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: Eric.Bateman@uct.ac.za. 2. Takeda Pharmaceuticals International GmbH, Zurich, Switzerland. 3. Boehringer Ingelheim Pharma GmbH & Co, Biberach, Germany. 4. Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Centre North, Member of the German Center for Lung Research, Grosshansdorf, Germany.
Abstract
BACKGROUND:Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists. OBJECTIVE: We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast and montelukast versus montelukast alone in patients with moderate-to-severe asthma. METHODS: In a phase 2, randomized, double-blind, placebo-controlled, multiple-dose, 2-sequence, crossover study, 64 patients were randomized to receive 500 μg of roflumilast plus montelukast followed by placebo plus 10 mg of montelukast (sequence AB) or placebo plus 10 mg of montelukast followed by 500 μg of roflumilast plus 10 mg of montelukast (sequence BA). All patients had a diagnosis of bronchial asthma inadequately controlled by at least a medium-dose inhaledcorticosteroid plus a long-acting β-agonist. RESULTS: The analysis of FEV1 change from baseline to week 4 showed a statistically significant and clinically meaningful treatment difference of 100 mL for roflumilast plus montelukast versus placebo plus montelukast. Also, improvements in patient-reported outcomes and a reduction in urinary leukotriene E4 levels were observed during roflumilast plus montelukast treatment compared with placebo plus montelukast treatment. Adverse events were consistent with the known safety profile of roflumilast. CONCLUSION: The combination of roflumilast with montelukast compared with montelukast alone improved lung function and asthma control in patients with moderate-to-severe asthma and deserves further study for this indication.
RCT Entities:
BACKGROUND:Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists. OBJECTIVE: We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast and montelukast versus montelukast alone in patients with moderate-to-severe asthma. METHODS: In a phase 2, randomized, double-blind, placebo-controlled, multiple-dose, 2-sequence, crossover study, 64 patients were randomized to receive 500 μg of roflumilast plus montelukast followed by placebo plus 10 mg of montelukast (sequence AB) or placebo plus 10 mg of montelukast followed by 500 μg of roflumilast plus 10 mg of montelukast (sequence BA). All patients had a diagnosis of bronchial asthma inadequately controlled by at least a medium-dose inhaled corticosteroid plus a long-acting β-agonist. RESULTS: The analysis of FEV1 change from baseline to week 4 showed a statistically significant and clinically meaningful treatment difference of 100 mL for roflumilast plus montelukast versus placebo plus montelukast. Also, improvements in patient-reported outcomes and a reduction in urinary leukotriene E4 levels were observed during roflumilast plus montelukast treatment compared with placebo plus montelukast treatment. Adverse events were consistent with the known safety profile of roflumilast. CONCLUSION: The combination of roflumilast with montelukast compared with montelukast alone improved lung function and asthma control in patients with moderate-to-severe asthma and deserves further study for this indication.
Authors: Bhupendrasinh F Chauhan; Maya M Jeyaraman; Amrinder Singh Mann; Justin Lys; Ahmed M Abou-Setta; Ryan Zarychanski; Francine M Ducharme Journal: Cochrane Database Syst Rev Date: 2017-03-16
Authors: Gene T Yocum; Julie J Hwang; Maya Mikami; Jennifer Danielsson; Aisha S Kuforiji; Charles W Emala Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-12-04 Impact factor: 5.464
Authors: Antonio Di Gennaro; Ana Carolina Araújo; Albert Busch; Hong Jin; Dick Wågsäter; Emina Vorkapic; Kenneth Caidahl; Per Eriksson; Bengt Samuelsson; Lars Maegdefessel; Jesper Z Haeggström Journal: Proc Natl Acad Sci U S A Date: 2018-02-05 Impact factor: 11.205
Authors: Celeste Porsbjerg; Charlotte Ulrik; Tina Skjold; Vibeke Backer; Birger Laerum; Sverre Lehman; Crister Janson; Thomas Sandstrøm; Leif Bjermer; Barbro Dahlen; Bo Lundbäck; Dora Ludviksdottir; Unnur Björnsdóttir; Alan Altraja; Lauri Lehtimäki; Paula Kauppi; Jussi Karjalainen; Hannu Kankaanranta Journal: Eur Clin Respir J Date: 2018-03-06
Authors: Luis Pérez de Llano; Marc Miravitlles; Rafael Golpe; Francisco Javier Alvarez-Gutiérrez; Carolina Cisneros; Carlos Almonacid; Eva Martinez-Moragon; Francisco-Javier Gonzalez-Barcala; David Ramos-Barbón; Vicente Plaza; Jose Luis Lopez-Campos; Juan Pablo de-Torres; Ciro Casanova; Juan Luis Garcia Rivero; Juan Rodriguez Hermosa; Myriam Calle Rubio; Juan Jose Soler-Cataluña; Borja G Cosio Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-09-04
Authors: Diego J Maselli; Megan Hardin; Stephanie A Christenson; Nicola A Hanania; Craig P Hersh; Sandra G Adams; Antonio Anzueto; Jay I Peters; MeiLan K Han; Fernando J Martinez Journal: Chest Date: 2018-08-02 Impact factor: 10.262
Authors: Giorgio Walter Canonica; Gianenrico Senna; Patrick D Mitchell; Paul M O'Byrne; Giovanni Passalacqua; Gilda Varricchi Journal: World Allergy Organ J Date: 2016-11-28 Impact factor: 4.084
Authors: Ángel Agis-Torres; Paz Recio; María Elvira López-Oliva; María Pilar Martínez; María Victoria Barahona; Sara Benedito; Salvador Bustamante; Miguel Ángel Jiménez-Cidre; Albino García-Sacristán; Dolores Prieto; Vítor S Fernandes; Medardo Hernández Journal: Sci Rep Date: 2018-03-16 Impact factor: 4.379